Abstract
Background: Anti-PD-1/L1 antibodies could be an optional therapy for EGFR-TKI-resistant non-small cell lung cancer (NSCLC) patients with EGFR mutation. However, little is known about PD-L1 expression in advanced NSCLC patients with the T790M-positive EGFR mutation, as well as the changes induced by osimertinib treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
